A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

BACKGROUND: Treatment for TB is lengthy and toxic, and new regimens are needed. METHODS: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin (M) and 1500 mg pyrazinamide (Z) for 6 months (6Pa(200)MZ) or 4 months (...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Tuberc Lung Dis
Hlavní autoři: Tweed, C. D., Wills, G. H., Crook, A. M., Amukoye, E., Balanag, V., Ban, A. Y.L., Bateson, A. L.C., Betteridge, M. C., Brumskine, W., Caoili, J., Chaisson, R. E., Cevik, M., Conradie, F., Dawson, R., del Parigi, A., Diacon, A., Everitt, D. E., Fabiane, S.M., Hunt, R., Ismail, A. I., Lalloo, U., Lombard, L., Louw, C., Malahleha, M., McHugh, T. D., Mendel, C. M., Mhimbira, F., Moodliar, R. N., Nduba, V., Nunn, A. J., Sabi, I., Sebe, M. A., Selepe, R. A. P., Staples, S., Swindells, S., van Niekerk, C. H., Variava, E., Spigelman, M., Gillespie, S. H.
Médium: Artigo
Jazyk:Inglês
Vydáno: International Union Against Tuberculosis and Lung Disease 2021
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8009598/
https://ncbi.nlm.nih.gov/pubmed/33762075
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5588/ijtld.20.0513
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky